• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝脏中的解毒途径。

Detoxification pathways in the liver.

作者信息

Grant D M

机构信息

Division of Clinical Pharmacology and Toxicology, Hospital for Sick Children, Toronto, Ontario, Canada.

出版信息

J Inherit Metab Dis. 1991;14(4):421-30. doi: 10.1007/BF01797915.

DOI:10.1007/BF01797915
PMID:1749210
Abstract

The liver plays an important rôle in protecting the organism from potentially toxic chemical insults through its capacity to convert lipophiles into more water-soluble metabolites which can be efficiently eliminated from the body via the urine. This protective ability of the liver stems from the expression of a wide variety of xenobiotic biotransforming enzymes whose common underlying feature is their ability to catalyse the oxidation, reduction and hydrolysis (Phase I) and/or conjugation (Phase II) of functional groups on drug and chemical molecules. The broad substrate specificity, isoenzyme multiplicity and inducibility of many of these enzyme systems make them particularly well adapted to handling the vast array of different chemical structures in the environment to which we are exposed daily. However, some chemicals may also be converted to more toxic metabolites by certain of these enzymes, implying that variations in the latter may be important predisposing factors for toxicity. Pharmacogenetic defects of xenobiotic biotransformation enzymes, a subclass of inborn errors of metabolism which are manifested only upon drug challenge, introduce marked variation into human populations for the pharmacokinetics and pharmacodynamics of therapeutic and toxic agents, and thus may have important clinical consequences for drug efficacy and toxicity.

摘要

肝脏在保护机体免受潜在有毒化学物质侵害方面发挥着重要作用,它能够将亲脂性物质转化为水溶性更高的代谢产物,这些代谢产物可通过尿液有效地从体内排出。肝脏的这种保护能力源于多种外源性生物转化酶的表达,这些酶的共同基本特征是能够催化药物和化学分子上功能基团的氧化、还原和水解(I相)以及/或结合反应(II相)。许多这些酶系统具有广泛的底物特异性、同工酶多样性和可诱导性,这使得它们特别适合处理我们每天接触到的环境中大量不同的化学结构。然而,某些化学物质也可能被其中某些酶转化为毒性更强的代谢产物,这意味着这些酶的变异可能是毒性的重要易感因素。外源性生物转化酶的药物遗传学缺陷是代谢先天性疾病的一个亚类,仅在药物激发时才会表现出来,它会给人群中治疗药物和毒性药物的药代动力学和药效学带来显著差异,因此可能对药物疗效和毒性产生重要的临床影响。

相似文献

1
Detoxification pathways in the liver.肝脏中的解毒途径。
J Inherit Metab Dis. 1991;14(4):421-30. doi: 10.1007/BF01797915.
2
Nuclear pregnane x receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification.核孕烷X受体以及组成型雄烷受体调控参与外源性物质解毒的重叠但不同的基因集。
Mol Pharmacol. 2002 Sep;62(3):638-46. doi: 10.1124/mol.62.3.638.
3
Structural and functional characterization of microcystin detoxification-related liver genes in a phytoplanktivorous fish, Nile tilapia (Oreochromis niloticus).植食性鱼类尼罗罗非鱼(Oreochromis niloticus)中微囊藻毒素解毒相关肝脏基因的结构与功能表征
Comp Biochem Physiol C Toxicol Pharmacol. 2006 Nov;144(3):216-27. doi: 10.1016/j.cbpc.2006.08.009. Epub 2006 Sep 3.
4
Phase II enzymes and bioactivation.II期酶与生物活化作用
Can J Physiol Pharmacol. 1995 Oct;73(10):1407-13. doi: 10.1139/y95-196.
5
Advances in drug metabolism and pharmacogenetics research in Australia.澳大利亚药物代谢与药物遗传学研究进展。
Pharmacol Res. 2017 Feb;116:7-19. doi: 10.1016/j.phrs.2016.12.008. Epub 2016 Dec 9.
6
[Toxic liver injuries--a current view on pathogenesis. Part II].[中毒性肝损伤——发病机制的当前观点。第二部分]
Med Pr. 2011;62(2):203-10.
7
Discovery of a widespread metabolic pathway within and among phenolic xenobiotics.酚类异生物质内部和之间广泛代谢途径的发现。
Proc Natl Acad Sci U S A. 2017 Jun 6;114(23):6062-6067. doi: 10.1073/pnas.1700558114. Epub 2017 May 23.
8
Hereditary variation of liver enzymes involved with detoxification and neurodegenerative disease.参与解毒和神经退行性疾病的肝脏酶的遗传变异。
J Inherit Metab Dis. 1991;14(4):431-5. doi: 10.1007/BF01797916.
9
Metabolic activation as a basis for organ-selective toxicity.代谢活化作为器官选择性毒性的基础。
Clin Exp Pharmacol Physiol. 1983 Jan-Feb;10(1):87-99. doi: 10.1111/j.1440-1681.1983.tb00175.x.
10
Interaction of ethanol with drugs, hepatotoxic agents, carcinogens and vitamins.乙醇与药物、肝毒性物质、致癌物及维生素的相互作用。
Alcohol Alcohol. 1990;25(2-3):157-76. doi: 10.1093/oxfordjournals.alcalc.a044990.

引用本文的文献

1
Does Genetic Variation in Detoxification Capacity Influence Hepatic Biomarker Responses to a Liver Support Supplementation Regimen?解毒能力的基因变异是否会影响肝脏生物标志物对肝脏支持补充方案的反应?
Int J Mol Sci. 2025 Oct 20;26(20):10209. doi: 10.3390/ijms262010209.
2
Segmented regression modeling of a phytogenic blend on growth and immune function in broilers: a dose-response study.植物源混合饲料对肉鸡生长和免疫功能的分段回归建模:剂量反应研究
Poult Sci. 2025 Dec;104(12):105913. doi: 10.1016/j.psj.2025.105913. Epub 2025 Sep 27.
3
Liver immunology: Biological role and clinical significance.

本文引用的文献

1
A simple test for acetylator phenotype using caffeine.一种使用咖啡因检测乙酰化酶表型的简单测试。
Br J Clin Pharmacol. 1984 Apr;17(4):459-64. doi: 10.1111/j.1365-2125.1984.tb02372.x.
2
In vitro assessment of pharmacogenetic susceptibility to toxic drug metabolites in humans.
Fed Proc. 1984 May 15;43(8):2308-13.
3
The molecular biology of cytochrome P450s.细胞色素P450的分子生物学
Pharmacol Rev. 1988 Dec;40(4):243-88.
肝脏免疫学:生物学作用及临床意义。
World J Hepatol. 2025 Jul 27;17(7):107541. doi: 10.4254/wjh.v17.i7.107541.
4
Complex system modeling reveals oxalate homeostasis is driven by diverse oxalate-degrading bacteria.复杂系统建模显示,草酸盐稳态由多种草酸盐降解细菌驱动。
Elife. 2025 May 1;14:RP104121. doi: 10.7554/eLife.104121.
5
Effects of Benzo[k]fluoranthene at Two Temperatures on Viability, Structure, and Detoxification-Related Genes in Rainbow Trout RTL-W1 Cell Spheroids.两种温度下苯并[k]荧蒽对虹鳟鱼RTL-W1细胞球体活力、结构及解毒相关基因的影响
Toxics. 2025 Apr 12;13(4):302. doi: 10.3390/toxics13040302.
6
In vitro cytotoxicity evaluation of a CMC-SA edible packaging film for migration and safety assessment.用于迁移和安全性评估的羧甲基纤维素-海藻酸钠可食用包装膜的体外细胞毒性评价
Sci Rep. 2025 Apr 17;15(1):13304. doi: 10.1038/s41598-025-98163-0.
7
Nanomaterials for liver cancer targeting: research progress and future prospects.用于肝癌靶向的纳米材料:研究进展与未来展望
Front Immunol. 2025 Feb 28;16:1496498. doi: 10.3389/fimmu.2025.1496498. eCollection 2025.
8
Risk Assessment Arising from the Exposure of Terrestrial Vertebrates to Soil Contamination: Learning from Field Lizards of the Genus.陆生脊椎动物接触土壤污染产生的风险评估:从该属的野外蜥蜴中获取经验。
J Xenobiot. 2025 Feb 1;15(1):21. doi: 10.3390/jox15010021.
9
An Nrf2-NF-κB Crosstalk Controls Hepatocyte Proliferation in the Normal and Injured Liver.Nrf2与NF-κB的相互作用调控正常及损伤肝脏中的肝细胞增殖。
Cell Mol Gastroenterol Hepatol. 2025;19(7):101480. doi: 10.1016/j.jcmgh.2025.101480. Epub 2025 Feb 17.
10
Delivering miR-23b-3p by small extracellular vesicles to promote cell senescence and aberrant lipid metabolism.通过小细胞外囊泡递送miR-23b-3p以促进细胞衰老和异常脂质代谢。
BMC Biol. 2025 Feb 11;23(1):41. doi: 10.1186/s12915-025-02143-9.
4
Evidence for two closely related isozymes of arylamine N-acetyltransferase in human liver.人肝脏中两种密切相关的芳胺N - 乙酰转移酶同工酶的证据。
FEBS Lett. 1989 Feb 13;244(1):203-7. doi: 10.1016/0014-5793(89)81193-7.
5
Evolution of the cytochrome P450 genes.
Xenobiotica. 1989 Oct;19(10):1149-60. doi: 10.3109/00498258909043167.
6
N-acetyltransferase.N-乙酰基转移酶
Pharmacol Ther. 1989;42(2):157-234. doi: 10.1016/0163-7258(89)90036-3.
7
N-acetylation pharmacogenetics: a gene deletion causes absence of arylamine N-acetyltransferase in liver of slow acetylator rabbits.N-乙酰化药物遗传学:基因缺失导致慢乙酰化兔肝脏中芳胺N-乙酰转移酶缺乏。
Proc Natl Acad Sci U S A. 1989 Dec;86(23):9554-7. doi: 10.1073/pnas.86.23.9554.
8
Enzyme induction in the cytochrome P-450 system.
Pharmacol Ther. 1990;45(2):241-98. doi: 10.1016/0163-7258(90)90030-6.
9
Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression.
DNA Cell Biol. 1990 Apr;9(3):193-203. doi: 10.1089/dna.1990.9.193.
10
Acetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver.乙酰化药物遗传学。慢乙酰化者表型是由人肝脏中芳胺N - 乙酰转移酶减少或缺乏所致。
J Clin Invest. 1990 Mar;85(3):968-72. doi: 10.1172/JCI114527.